Loading...
Loading...
Aegerion Pharmaceuticals,
Inc.
AEGR, an emerging biopharmaceutical company focused on the
development and commercialization of novel therapeutics to treat severe lipid
disorders, today provided a clinical update on its lead investigational
therapeutic, lomitapide.
Aegerion reported that the 78-week data from its pivotal Phase III clinical
trial are consistent with data previously reported at the 26- and 56-week time
points. The Phase III study was a single-arm, open label trial, designed to
evaluate the efficacy and long-term safety of lomitapide for the treatment of
patients with homozygous familial hypercholesterolemia (HoFH). The data
demonstrate that the reduction in LDL-C cholesterol from baseline was
maintained at 78-weeks.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in